Article
p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.
Cancer - 15 Sept 1996
Safran H, King T, Choy H, Gollerkeri A, Kwakwa H, Lopez F, Cole B, Myers J, Tarpey J, Rosmarin A
Abstract excerpt
BACKGROUND: Mutations in the tumor suppressor gene p53 have been associated with resistance to ionizing radiation and chemotherapy. Paclitaxel and concurrent radiation (paclitaxel/RT) achieve high response rates with locally advanced nonsmall cell lung carcinoma (NSCLC). In vitro data and animal studies suggest that paclitaxel may have a unique ability to activate tumor cell apoptosis in the absence of wild-type...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.